Literature DB >> 3784306

Effects of acute and chronic dosing of NSAIDs in patients with renal insufficiency.

R D Toto, S A Anderson, D Brown-Cartwright, J P Kokko, D C Brater.   

Abstract

Administration of nonsteroidal anti-inflammatory drugs (NSAIDs) to patients with chronically impaired renal function has been reported to cause abrupt and sustained reductions in renal plasma flow (RPF), glomerular filtration rate (GFR), and solute and water excretion in association with decreased renal prostanoid production. However, the time course of these acute effects and whether they are sustained during chronic exposure to the NSAIDs are unknown. Accordingly, using standard clearance and balance techniques, we investigated the effects of acute (zero to four hours) and chronic (five days) oral administration of two different NSAIDs on renal function in patients with stable, mild to moderate chronic renal insufficiency (CRI) and in normal subjects. In patients, acute oral administration of ketoprofen (K) and indomethacin (I) resulted in significant decreases in GFR (K: from 36 +/- 3 to 20 +/- 4 ml/min, P = 0.001; I: from 37 +/- 6 to 30 +/- 7 ml/min, P = 0.032; in RPF (K: from 194 +/- 21 to 146 +/- 21 ml/min, P = 0.002; I: from 222 +/- 33 to 147 +/- 18 ml/min, P = 0.016); and in urinary PGE2 excretion (K: from 0.60 +/- 0.25 to 0.08 +/- 0.02 ng/min, P = 0.05; I: from 0.34 +/- 0.06 to 0.18 +/- 0.06 ng/min, P = 0.042). Fractional excretion of sodium chloride and fractional free water clearance (CH2O/CIn) also decreased significantly after both agents. In normal subjects, GFR and RPF were not significantly decreased after acute dosing, whereas urinary PGE2 and fractional excretions of NaCl and free water decreased significantly.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3784306     DOI: 10.1038/ki.1986.253

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

1.  Evaluating the effects of diclofenac sodium and etodolac on renal hemodynamics with contrast-enhanced ultrasonography: a pilot study.

Authors:  Hiroshi Imamura; Jiro Hata; Ai Iida; Noriaki Manabe; Ken Haruma
Journal:  Eur J Clin Pharmacol       Date:  2012-06-26       Impact factor: 2.953

2.  Effects of flurbiprofen on renal function in patients with moderate renal insufficiency.

Authors:  M D Murray; P K Greene; D C Brater; A K Manatunga; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

Review 3.  Nonsteroidal anti-inflammatory drugs and acute renal failure in the elderly. A risk-benefit assessment.

Authors:  W Ailabouni; G Eknoyan
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

4.  Acute kidney injury following bariatric surgery.

Authors:  Toby N Weingarten; Carmelina Gurrieri; Joan M McCaffrey; Starla J Ricter; Mandy L Hilgeman; Darrell R Schroeder; Michael L Kendrick; Eddie L Greene; Juraj Sprung
Journal:  Obes Surg       Date:  2013-01       Impact factor: 4.129

5.  Effect of routine pre-anesthetic laboratory screening on pre-operative anesthesia-related decision-making in healthy dogs.

Authors:  Krista Mitchell; Michele Barletta; Jane Quandt; Molly Shepard; Stephanie Kleine; Erik Hofmeister
Journal:  Can Vet J       Date:  2018-07       Impact factor: 1.008

6.  Sulfate homeostasis. III. Effect of chronic naproxen or sulindac treatment on inorganic sulfate disposition in arthritic patients with renal impairment.

Authors:  M E Morris; J P Freer; W A Watson
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

Review 7.  Nephrotoxic drugs.

Authors:  S A Mendoza
Journal:  Pediatr Nephrol       Date:  1988-10       Impact factor: 3.714

Review 8.  Prostanoids in paediatric kidney diseases.

Authors:  H W Seyberth; A Leonhardt; B Tönshoff; N Gordjani
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714

Review 9.  A risk-benefit appraisal of injectable NSAIDs in the management of postoperative pain.

Authors:  L S Nuutinen; J O Laitinen; T E Salomäki
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.